English
Regional settings| Spread | 0.130 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.022091% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.000132% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | EUR | ||||
| Min traded quantity | 0.001 | ||||
| Margin | 20 | ||||
| Stock exchange | Germany | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 39.16 |
| Open | 38.59 |
| 1-Year Change | -4.49% |
| Day's Range | 38.575 - 39.48 |
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
BRIEF: For the fiscal year ended 31 December 2021, Qiagen NV revenues increased 20% to $2.25B. Net income increased 43% to $512.6M. Revenues reflect Consumables and Related Revenues segment increase of 23% to $1.99B, Instrumentation segment increase of 4% to $265.3M, United States segment increase of 25% to $909.7M, Europe & Middle East & Afric segment increase of 19% to $814.4M. Net income benefited from Restructuring decrease of 81% to $27.8M (expense).
1/2017, Shares Consolidation (Factor: 0.96296).
